



# Oncogenic potential of histone-variant H2A.Z.1 and its regulatory role in cell cycle and epithelial-mesenchymal transition in liver cancer


## Supplementary Materials




**Supplementary Figure S1: Aberrant expression of *H2afz* in a subset of mouse HCC.** Analysis of microarray data from the Gene Expression Omnibus (GEO) database. GSE data sets of GSE29813, GSE35289, and GSE57597 showed that *H2afz* was significantly overexpressed in mouse HCC. Upper panel: *H2afz* mRNA expression in mouse HCC. Lower panel: *H2afv* mRNA expression in mouse HCC (mean  $\pm$  S.D., \*\* $P < 0.01$ , \* $P < 0.05$ , versus Non-tumor).




**Supplementary Figure S2: The *H2AFZ* gene expression in HCC patients with different etiologies.** GSE50579 and GSE16757 showed that *H2AFZ* was significantly overexpressed regardless HBV or HCV etiology. Comparison of *H2AFZ* expression in HCC patients with HBV(+) and HCV(+) versus non-tumor (GSE50579) or HBV(+) and HBV(-) versus non-tumor (GSE16757) (mean  $\pm$  S.D., \*\*\* $P < 0.001$ , \*\* $P < 0.01$ , versus Non-tumor).



**Supplementary Figure S3: Western blot analysis of H2A.Z.1 expressing plasmid in liver cell lines.** (A) After 48 hr transfection, cell lysate was obtained and western blot analysis was performed to specific antibodies. (B) Each pcDNA3.1\_Mock or pcDNA3.1\_H2A.Z.1 plasmid was transfected into MIHA cells. After 48 hr incubation, the western blot analysis was performed for detection of endogenous or exogenous H2A.Z.1 protein.



**Supplementary Figure S4: An enrichment network analysis that linked *H2AFZ* signatures with cellular pathways.** *H2AFZ*-associated genes were analyzed by using the molecular concept map (ConceptGen). Four major molecular concepts were indicated by colored circles.



**Supplementary Figure S5: Effect of TGF- $\beta$  on E-cadherin and fibronectin expression in liver cancer cells.** The western blot analysis was performed and the protein levels of E-cadherin and fibronectin were detected by specific antibodies. The GAPDH was used for a loading control.

**Supplementary Table S1: *H2AFZ* and *H2AFV* expression in HCC GEO datasets**

GEO No.	GSE14520		GSE16757		GSE22058		GSE36376	
cohort	(N = 220, T = 225)		(N = 20, T = 100)		(N = 97, T = 100)		(N = 193, T = 240)	
	Fold change	P value	Fold change	P value	Fold change	P value	Fold change	P value
<i>H2AFZ</i>	2.771	$p < 0.001$	2.126	$p < 0.001$	1.535	$p < 0.001$	2.279	$p < 0.001$
<i>H2AFV</i>	1.154	$p < 0.001$	1.015	ns	1.112	$p < 0.01$	1.098	$p < 0.001$

**Supplementary Table S2: *H2AFZ*-associated functional annotation cluster list**

Cluster No.	Title	Term	Count	p value
1	Cell Cycle	cell cycle phase	45	$p < 0.001$
		cell cycle	58	$p < 0.001$
		M phase	36	$p < 0.001$
		cell cycle process	47	$p < 0.001$
		mitotic cell cycle	36	$p < 0.001$
		organelle fission	25	$p < 0.001$
		mitosis	24	$p < 0.001$
		nuclear division	24	$p < 0.001$
		M phase of mitotic cell cycle	24	$p < 0.001$
		cell division	23	$p < 0.001$
2	DNA Repair	DNA metabolic process	45	$p < 0.001$
		DNA repair	26	$p < 0.001$
		response to DNA damage stimulus	30	$p < 0.001$
		cellular response to stress	33	$p < 0.001$
3	Nuclear Lumen	organelle lumen	82	$p < 0.001$
		nucleoplasm	51	$p < 0.001$
		intracellular organelle lumen	80	$p < 0.001$
		membrane-enclosed lumen	82	$p < 0.001$
		nuclear lumen	66	$p < 0.001$

4	<b>Chromosome</b>	chromosome	44	$p < 0.001$
		chromosomal part	37	$p < 0.001$
		condensed chromosome	20	$p < 0.001$
		chromosome, centromeric region	18	$p < 0.001$
		kinetochore	13	$p < 0.001$
		condensed chromosome, centromeric region	12	$p < 0.001$
		condensed chromosome kinetochore	11	$p < 0.001$
		chromosome segregation	11	$p < 0.001$
		non-membrane-bounded organelle	88	$p < 0.001$
		intracellular non-membrane-bounded organelle	88	$p < 0.001$
5	<b>Mitosis</b>	mitotic cell cycle	36	$p < 0.001$
		interphase of mitotic cell cycle	15	$p < 0.001$
		interphase	15	$p < 0.001$
		G1/S transition of mitotic cell cycle	8	$p < 0.001$
6	<b>Macromolecule Assembly</b>	macromolecular complex subunit organization	39	$p < 0.001$
		macromolecular complex assembly	35	$p < 0.001$
		cellular macromolecular complex subunit organization	23	$p < 0.001$
		cellular macromolecular complex assembly	19	$p < 0.001$
		protein complex biogenesis	25	$p < 0.01$
		protein complex assembly	25	$p < 0.01$
7	<b>Meiosis</b>	DNA recombination	13	$p < 0.001$
		meiotic cell cycle	12	$p < 0.001$
		M phase of meiotic cell cycle	11	$p < 0.001$
		meiosis	11	$p < 0.001$
		reciprocal meiotic recombination	4	$p < 0.05$
		meiosis I	4	n.s
8	<b>Microtubule Process</b>	microtubule cytoskeleton organization	14	$p < 0.001$
		spindle organization	8	$p < 0.001$
		microtubule-based process	17	$p < 0.001$
		cytoskeleton organization	19	$p < 0.05$

9	ATPase Activity	DNA-dependent ATPase activity	9	$p < 0.001$
		ATPase activity	20	$p < 0.001$
		ATPase activity, coupled	15	$p < 0.01$
10	DNA Replication	replication fork	8	$p < 0.001$
		DNA replication factor C complex	4	$p < 0.001$
		nucleotide-excision repair, DNA gap filling	5	$p < 0.001$
		DNA clamp loader activity	3	$p < 0.001$
		protein-DNA loading ATPase activity	3	$p < 0.01$
		nucleotide-excision repair	6	$p < 0.01$

**Supplementary Table S3: Positive enrichment gene sets of *H2AFZ* high**

No.	Gene Sets	SIZE	ES	NES
1	REACTOME_CELL_CYCLE	42	0.65	1.35
2	REACTOME_CELL_CYCLE_MITOTIC	38	0.64	1.32
3	REACTOME_MITOTIC_M_M_G1_PHASES	23	0.66	1.28
4	REACTOME_MITOTIC_PROMETAPHASE	16	0.62	1.24
5	REACTOME_DNA_REPLICATION	28	0.6	1.2
6	REACTOME_ADAPTIVE_IMMUNE_SYSTEM	17	0.4	1.16
7	REACTOME_IMMUNE_SYSTEM	25	0.24	0.76
8	REACTOME_HEMOSTASIS	22	0.18	0.55
9	REACTOME_METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS	16	0.19	0.53